According to the World Health Organisation (WHO) and the World Federation of Hemophilia around two thirds of the haemophilia patient population receive inadequate or no treatment at all.
Total sales of recombinant Factor VIII products in 2018 were $6BN but the quantity behind this number is still only enough for treating less than 25% of the estimated number of patients in the triad (USA, Japan, Western Europe).read more
Profactor Pharma Ltd is pleased to announce the appointment of Dr V Paul Gerskowitch to its board. Dr Gerskowitch joins the board of Profactor Pharma Ltd as an Investor Director with extensive, board level experience in the life sciences industries. He currently...read more